Stockscreener 앱 받기
0.828
2.16%
0.0175
Pharmacyte Biotech Inc 주식(PMCB)의 최신 뉴스
PharmaCyte Biotech (PMCB) Holds Steady at $0.7: Consolidation Near Key SupportVolume Profile - newsline.com
PMCB Technical Analysis & Stock Price Forecast - Intellectia AI
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Pre‑Revenue Biotech Reports Loss, Shares Slide 3.5%Earnings Surprise Stocks - newsline.com
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023. - marketscreener.com
PharmaCyte Biotech (PMCB) Rises 3.19%: Approaching Resistance Zone Amid Biotech Sector FocusChaikin Flow - newsline.com
PharmaCyte Biotech (PMCB) Slips 3.3% as Stock Nears Critical Support at $0.79ETF NAV Deviation - newsline.com
PharmaCyte Biotech (PMCB) Jumps 12.76% as Biotech Speculation Heats UpBuyback Factor - The Legal Advocate
PharmaCyte Biotech (PMCB) Edges Higher: Support-Holding Action at $0.81IPO Entry Watch - Newser
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Negative EPS; Stock Rises on Potential Pipeline Progress - Newser
PharmaCyte Biotech Inc. (PMCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PharmaCyte Biotech (PMCB) Rallies 5.6% as Biotech Sentiment ImprovesNHNL Divergence - Newser
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Strategic Pipeline ProgressHigh Estimate Range - Newser
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Pre-Revenue Biotech Reports Wider Loss Amid Strategic Pipeline ProgressShared Momentum Picks - Newser
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Revenue $N/A, Matching ViewsGuidance Revision Trend - Newser
TradingKey - TradingKey
PharmaCyte Biotech (PMCB) Stock: Buy or Sell |Risk Report - newser.com
PMCB SEC FilingsPharmacyte Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
PharmaCyte Biotech (PMCB) Stock Take Profit (Gains) 2026-04-20Risk Reward Setups - newsline.com
Aug Intraday: Is PharmaCyte Biotech Inc a good ESG investment2026 Short Interest & Accurate Trade Setup Notifications - baoquankhu1.vn
PharmaCyte Biotech Operating Margin | PMCB - MLQ.ai
EV Market: Should I invest in PharmaCyte Biotech Inc before earningsJobs Report & Weekly High Return Opportunities - baoquankhu1.vn
How liquid is PharmaCyte Biotech Inc stockPortfolio Performance Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Is PharmaCyte Biotech (PMCB) Stock Near Support | Price at $0.69, Up 5.96%New Highs New Lows - newsline.com
Aug Ideas: What is the Moat Score of PharmaCyte Biotech Inc2026 EndofYear Setup & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is PharmaCyte Biotech Inc vulnerable to short sellersMarket Sentiment Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
PharmaCyte Biotech Shareholders Approve Governance and Equity Actions - The Globe and Mail
Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB) - Stock Titan
Director at PharmaCyte Biotech (PMCB) gets 119,170 options - Stock Titan
PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67 - Stock Titan
PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67 - Stock Titan
PharmaCyte Biotech (PMCB) wins approval for reverse split range and 2M new plan shares - Stock Titan
PMCB Stock Chart | PHARMACYTE BIOTECH INC (NASDAQ:PMCB) - ChartMill
Insider Sell: How liquid is PharmaCyte Biotech Inc stock2026 Setups & Safe Entry Momentum Tips - baoquankhu1.vn
PharmaCyte Biotech, Inc. (PMCB) Q3 2026 10-Q Report: Financial Results, Stock Information, and SEC Filings - Minichart
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD) - TradingView
PharmaCyte Biotech (NASDAQ: PMCB) details Jan 2026 results and cash runway - Stock Titan
PharmaCyte Biotech delays quarterly report filing - MSN
Analyzing Prime Medicine (NYSE:PRME) & PharmaCyte Biotech (OTCMKTS:PMCBD) - Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PharmaCyte Biotech (PMCB) seeks reverse split, equity plan boost at 2026 meeting - Stock Titan
Aug Catalysts: Can PharmaCyte Biotech Inc. stock weather global recessionWeekly Profit Summary & Safe Capital Growth Plans - Naître et grandir
PMCB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Technical Analysis - Intellectia AI
1.27%
1.43%
자본화:
|
볼륨(24시간):